Open AccessGuidance on the treatment of antipsychotic-induced hyperprolactinemia when switching the antipsychotic is not an option
Author(s) -
Matthew M. Rusgis,
Afaq Y Alabbasi,
Leigh Anne Nelson
Publication year - 2021
Publication title -
american journal of health-system pharmacy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.487
H-Index - 96
eISSN - 1535-2900
pISSN - 1079-2082
DOI - 10.1093/ajhp/zxab065
Subject(s) - cabergoline , aripiprazole , medicine , bromocriptine , antipsychotic , adverse effect , tolerability , discontinuation , pharmacology , prolactin , psychiatry , schizophrenia (object oriented programming) , hormone
This article aims to evaluate management options for antipsychotic-induced hyperprolactinemia and associated treatment considerations such as efficacy, tolerability, drug interactions, contraindications, and dosing regimens.